[go: up one dir, main page]

CA2392568A1 - Procede de prevention et/ou de traitement de l'atherosclerose - Google Patents

Procede de prevention et/ou de traitement de l'atherosclerose Download PDF

Info

Publication number
CA2392568A1
CA2392568A1 CA002392568A CA2392568A CA2392568A1 CA 2392568 A1 CA2392568 A1 CA 2392568A1 CA 002392568 A CA002392568 A CA 002392568A CA 2392568 A CA2392568 A CA 2392568A CA 2392568 A1 CA2392568 A1 CA 2392568A1
Authority
CA
Canada
Prior art keywords
lxr
ligand
receptor
patient
ppar
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002392568A
Other languages
English (en)
Inventor
Carl P. Sparrow
John G. Ondeyka
Sheo Bux Singh
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2392568A1 publication Critical patent/CA2392568A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Vascular Medicine (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

L'invention concerne un procédé d'élévation des taux sériques de cholestérol HDL, consistant à administrer une dose efficace sur le plan thérapeutique d'un ligand LXR à un patient nécessitant un tel traitement. L'invention concerne en outre un procédé d'utilisation d'un ligand LXR aux fins de stimulation de l'expression du gène ABC1. On peut utiliser des ligands LXR pour prévenir et traiter l'athérosclérose et des états associés.
CA002392568A 1999-12-13 2000-12-07 Procede de prevention et/ou de traitement de l'atherosclerose Abandoned CA2392568A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US17040399P 1999-12-13 1999-12-13
US60/170,403 1999-12-13
PCT/US2000/033098 WO2001041704A2 (fr) 1999-12-13 2000-12-07 Procede de prevention et/ou de traitement de l'atherosclerose

Publications (1)

Publication Number Publication Date
CA2392568A1 true CA2392568A1 (fr) 2001-06-14

Family

ID=22619728

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002392568A Abandoned CA2392568A1 (fr) 1999-12-13 2000-12-07 Procede de prevention et/ou de traitement de l'atherosclerose

Country Status (5)

Country Link
EP (1) EP1239855A4 (fr)
JP (1) JP2003516327A (fr)
AU (1) AU2064701A (fr)
CA (1) CA2392568A1 (fr)
WO (1) WO2001041704A2 (fr)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1854880A1 (fr) * 1999-03-15 2007-11-14 University of British Columbia Procédés et réactifs pour moduler les niveaux de cholestérol
AU784108B2 (en) 1999-03-15 2006-02-02 University Of British Columbia, The Methods and reagents for modulating cholesterol levels
US6821774B1 (en) 1999-06-18 2004-11-23 Cv Therapeutics, Inc. Compositions and methods for increasing cholesterol efflux and raising HDL using ATP binding cassette transporter ABC1
US6835563B1 (en) 1999-06-18 2004-12-28 Cv Therapeutics Compositions and methods for increasing cholesterol efflux and raising HDL ATP binding cassette transporter protein ABC1
JP2003520780A (ja) * 1999-09-01 2003-07-08 ユニバーシティ オブ ブリティッシュ コロンビア Ｈｄｌコレステロールとトリグリセリド水準を調節する組成物と方法
EP1203588A1 (fr) * 2000-11-06 2002-05-08 Bayer Ag Régulation stérol-indépendante du promoteur ABC1 par l' oncostatineM
US6908934B2 (en) * 2001-06-11 2005-06-21 Merck & Co., Inc. Therapeutic compounds for treating dyslipidemic conditions
WO2003031408A2 (fr) * 2001-10-08 2003-04-17 Eli Lilly And Company Composes tricycliques utiles pour moduler lxr
US6924311B2 (en) 2001-10-17 2005-08-02 X-Ceptor Therapeutics, Inc. Methods for affecting various diseases utilizing LXR compounds
GB2381866A (en) * 2001-11-12 2003-05-14 Karobio Ab Assays for liver X receptor (LXR) modulators
AU2003220521A1 (en) * 2002-03-27 2003-10-13 Smithkline Beecham Corporation Methods of treatment with lxr modulators
US7125865B2 (en) 2002-07-25 2006-10-24 Merck & Co., Inc. Therapeutic compounds for treating dyslipidemic conditions
WO2004050598A1 (fr) * 2002-12-03 2004-06-17 Kowa Co., Ltd. Procede pour preparer de l'anhydride acetylpodocarpique
JP2007516258A (ja) * 2003-12-12 2007-06-21 ワイス 心臓血管の疾患治療に有用なキノリン誘導体
KR101021828B1 (ko) 2004-10-27 2011-03-17 다이이찌 산쿄 가부시키가이샤 2 이상의 치환기를 갖는 벤젠 화합물
UA90718C2 (ru) 2005-05-10 2010-05-25 Лаборатуар Фурнье С.А. Новое применение агонистов печеночного рецептора х
WO2016057454A1 (fr) 2014-10-06 2016-04-14 The Johns Hopkins University Ciblage de récepteurs nucléaires de foie comme traitement pour la maladie de wilson
WO2018213082A1 (fr) * 2017-05-18 2018-11-22 Regeneron Pharmaceuticals, Inc. Bis-octahydrophénanthrène carboxamides et leurs conjugués protéiques
CA3120528A1 (fr) * 2018-11-20 2020-05-28 Regeneron Pharmaceuticals, Inc. Derives de bis-octahydrophenanthrene carboxamide et leurs conjugues proteiques destines a etre utilises en tant qu'agonistes de lxr
WO2020112889A2 (fr) 2018-11-26 2020-06-04 Denali Therapeutics Inc. Procédés de traitement du métabolisme lipidique dérégulé

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4444784A (en) * 1980-08-05 1984-04-24 Merck & Co., Inc. Antihypercholesterolemic compounds
WO1997028137A1 (fr) * 1996-02-02 1997-08-07 Merck & Co., Inc. Derives heterocycliques utilises comme agents contre le diabete et contre l'obesite
EP1458694A4 (fr) * 2001-12-20 2005-12-14 Merck & Co Inc Composes therapeutiques destines au traitement d'etats dyslipidemiques

Also Published As

Publication number Publication date
WO2001041704A3 (fr) 2001-12-06
WO2001041704A2 (fr) 2001-06-14
JP2003516327A (ja) 2003-05-13
EP1239855A4 (fr) 2004-04-21
AU2064701A (en) 2001-06-18
EP1239855A2 (fr) 2002-09-18

Similar Documents

Publication Publication Date Title
CA2392568A1 (fr) Procede de prevention et/ou de traitement de l'atherosclerose
US10343985B2 (en) Cryopyrin inhibitors for preventing and treating inflammation
US8569536B2 (en) C-nitroso-derived nitroxyl donors
JP2003525217A (ja) 肥満治療用薬剤
US20030086923A1 (en) Method for the prevention and/or treatment of atherosclerosis
JPWO1999004815A1 (ja) コレステロール低下作用を有する医薬組成物
AU2024227697A1 (en) Use of neutrophil elastase inhibitors in liver disease
US6908934B2 (en) Therapeutic compounds for treating dyslipidemic conditions
KR20020010581A (ko) 핵수용체 ｐｐａｒ의 신규한 리간드
McChesney et al. Metabolism of chloroquine and hydroxychloroquine in albino and pigmented rats
AU2020315606A1 (en) Compounds as NLRP3 inflammasome inhibitors and compositions and uses thereof
KR20030040225A (ko) 씨오엠티 저해효과를 가지는 쿠마린 유도체
CN114315754A (zh) 一种异羟肟酸类化合物及其用途
JP2008509912A (ja) 医薬品としての複素環化合物
JP2514163B2 (ja) ピリミドン誘導体及び類似化合物を含有する、喘息又は炎症性気道疾患の治療用医薬組成物
US20220184172A1 (en) Ampk/caspase-6 axis controls liver damage in nonalcoholic steatohepatitis
EP2045246A1 (fr) Dérivés de benzo[d] isothiazoles utilisés comme inhibiteurs des histone-désacétylases
US5149688A (en) Methods, compounds, and compositions for immunosuppression
US7081260B2 (en) α-Glucosidase inhibitors from a natural source
US6525098B1 (en) 6-methoxy-2-naphthylacetic acid prodrugs
US9839645B2 (en) Agents for killing HIV-1-infected cells and application thereof
US20050143346A1 (en) Composition for treating cancer containing n,n-dimethylphytosphingosine
AU707732B2 (en) 2-thioxotetrahydropyrimidin-4-one derivatives
WO2006007794A1 (fr) Derives de stilbene cis-1,2-substitues et utilisation de ceux-ci pour la preparation de medicaments servant au traitement ou a la prevention du diabete
TW201438717A (zh) 預防或治療蕭格倫徵候群之方法

Legal Events

Date Code Title Description
FZDC Correction of dead application (reinstatement)
FZDE Dead